Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure

Clinical Gastroenterology and Hepatology

Volumn 11, Issue 3, 2013, Pages 318-321

  Zelinkova, Zuzana ^a   van der Ent, Cokkie ^a   Bruin, Karlien F ^b   van Baalen, Onno ^c   Vermeulen, Hestia G ^d   Smalbraak, Herman J T ^e   Ouwendijk, Rob J ^d   Hoek, Aad C ^f   van der Werf, Sjoerd D ^g   Kuipers, Ernst J ^a   van der Woude, C Janneke ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CPRLab   (Netherlands)

^c RIVAS Beatrix Ziekenhuis   (Netherlands)

^d IKAZIA HOSPITAL   (Netherlands)

^e Lievensberg Ziekenhuis   (Netherlands)

^f Van Weel Bethesda Ziekenhuis   (Netherlands)

^g MEDICAL CENTER HAAGLANDEN   (Netherlands)

Author keywords

Anti TNF; Inflammatory Bowel Disease; Pregnancy

Indexed keywords

ADALIMUMAB; INFLIXIMAB; MERCAPTOPURINE;

ADULT; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; DISEASE ACTIVITY; DISEASE COURSE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; NEWBORN; RELAPSE; SPONTANEOUS ABORTION; UMBILICAL CORD BLOOD;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; FETAL BLOOD; HUMANS; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; INFLAMMATORY BOWEL DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS; TUMOR NECROSIS FACTOR-ALPHA; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84874569090     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2012.10.024     Document Type: Article

References (13)

1. Zelinkova Z., Mensink P.B., Dees J., et al. Reproductive wish represents an important factor influencing therapeutic strategy in inflammatory bowel diseases. Scand J Gastroenterol 2010, 45:46-50.
2. Heetun Z.S., Byrnes C., Neary P., et al. Review article: reproduction in the patient with inflammatory bowel disease. Aliment Pharmacol Ther 2007, 26:513-533.
3. Johnson D.L., Jones K.L., Chambers C.D., et al. Pregnancy outcomes in women exposed to adalimumab: the OTIS autoimmune diseases in pregnancy project. Gastroenterology 2009, 136(Suppl 1):A27.
4. Katz J.A., Antoni C., Keenan G.F., et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004, 99:2385-2392.
5. Lichtenstein G.R., Feagan B.G., Cohen R.D., et al. Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow-up in the TREAT registry. Am J Gastroenterol 2012, 107:1409-1422.
6. Schnitzler F., Fidder H., Ferrante M., et al. Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011, 17:1846-1854.
7. Mahadevan U., Martin C.F., Sandler R.S., et al. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy. Gastroenterology 2012, 149(Suppl 1):S149.
8. Mahadevan U., Terdiman J.P., Church J., et al. Infliximab levels in infants born to women with inflammatory bowel disease. Gastroenterology 2007, 132(Suppl 2):A144.
9. Vasiliauskas E.A., Church J.A., Silverman N., et al. Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol 2006, 4:1255-1258.
10. Zelinkova Z., de Haar C., de Ridder L., et al. High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011, 33:1053-1058.
11. van der Woude C.J., Kolacek S., Dotan I., et al. European evidenced-based consensus on reproduction in inflammatory bowel disease. J Crohns Colitis 2010, 4:493-510.
12. Mahadevan U., Kane S.V., Church J.A., et al. The effect of maternal peripartum infliximab use on neonatal immune response. Gastroenterology 2008, 134(Suppl 1):A69.
13. Cheent K., Nolan J., Shariq S., et al. Case report: fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease. J Crohns Colitis 2010, 4:603-605.